Gyre Therapeutics, Inc. (GYRE) stock
GYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 11/3014% below fair value
$4.34−0.22 (-4.82%)
Close on Nov 18, 2026Market cap $483.95MP/E –Yield –
Gyre Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Gyre Therapeutics's R&D Expenses for the twelve months ending Mar 31, 2026 was $27.70M, up 114.1% year over year. For fiscal 2025 it was $13.70M, up 13.9% from the year before. Over ten years it grew 8.7% a year on average. The highest annual figure on record is $95.22M in fiscal 2011.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.70M | +13.9% |
| FY2024 | Dec 31, 2024 | $12.02M | -12.7% |
| FY2023 | Dec 31, 2023 | $13.78M | -17.4% |
| FY2022 | Dec 31, 2022 | $16.69M | -75.8% |
| FY2021 | Dec 31, 2021 | $68.89M | +30.0% |
| FY2020 | Dec 31, 2020 | $52.98M | +20.8% |
| FY2019 | Dec 31, 2019 | $43.86M | +104.2% |
| FY2018 | Dec 31, 2018 | $21.47M | +67.2% |
| FY2017 | Dec 31, 2017 | $12.85M | +11.2% |
| FY2016 | Dec 31, 2016 | $11.56M | +93.9% |
| FY2015 | Dec 31, 2015 | $5.96M | +13.1% |
| FY2014 | Dec 31, 2014 | $5.27M | -19.7% |
| FY2013 | Dec 31, 2013 | $6.56M | -86.6% |
| FY2012 | Dec 31, 2012 | $49.09M | -48.4% |
| FY2011 | Dec 31, 2011 | $95.22M | +47.5% |
| FY2010 | Dec 31, 2010 | $64.55M | +60.6% |
| FY2009 | Dec 31, 2009 | $40.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $6.74M | +117.7% |
| Q4 FY2025 | Dec 31, 2025 | $4.82M | +29.7% |
| Q3 FY2025 | Sep 30, 2025 | $7.80M | +181.0% |
| Q2 FY2025 | Jun 30, 2025 | $8.35M | +148.9% |
| Q1 FY2025 | Mar 31, 2025 | $3.10M | +41.8% |
| Q4 FY2024 | Dec 31, 2024 | $3.71M | -18.7% |
| Q3 FY2024 | Sep 30, 2024 | $2.78M | -7.8% |
| Q2 FY2024 | Jun 30, 2024 | $3.36M | -6.0% |
| Q1 FY2024 | Mar 31, 2024 | $2.18M | -17.2% |
| Q4 FY2023 | Dec 31, 2023 | $4.57M | +6.0% |
| Q3 FY2023 | Sep 30, 2023 | $3.01M | +274.7% |
| Q2 FY2023 | Jun 30, 2023 | $3.57M | +90.7% |
| Q1 FY2023 | Mar 31, 2023 | $2.64M | -72.8% |
| Q4 FY2022 | Dec 31, 2022 | $4.31M | -73.3% |
| Q3 FY2022 | Sep 30, 2022 | $803.00K | -96.1% |
| Q2 FY2022 | Jun 30, 2022 | $1.87M | -87.8% |
| Q1 FY2022 | Mar 31, 2022 | $9.70M | -43.0% |
| Q4 FY2021 | Dec 31, 2021 | $16.14M | +10.8% |
| Q3 FY2021 | Sep 30, 2021 | $20.35M | +66.2% |
| Q2 FY2021 | Jun 30, 2021 | $15.39M | +19.2% |
| Q1 FY2021 | Mar 31, 2021 | $17.01M | +28.3% |
| Q4 FY2020 | Dec 31, 2020 | $14.56M | +34.9% |
| Q3 FY2020 | Sep 30, 2020 | $12.25M | +23.4% |
| Q2 FY2020 | Jun 30, 2020 | $12.91M | +16.2% |
| Q1 FY2020 | Mar 31, 2020 | $13.26M | +10.3% |
| Q4 FY2019 | Dec 31, 2019 | $10.79M | +31.0% |
| Q3 FY2019 | Sep 30, 2019 | $9.93M | +78.1% |
| Q2 FY2019 | Jun 30, 2019 | $11.11M | +185.7% |
| Q1 FY2019 | Mar 31, 2019 | $12.03M | +218.9% |
| Q4 FY2018 | Dec 31, 2018 | $8.24M | +131.4% |
| Q3 FY2018 | Sep 30, 2018 | $5.58M | +46.5% |
| Q2 FY2018 | Jun 30, 2018 | $3.89M | +14.3% |
| Q1 FY2018 | Mar 31, 2018 | $3.77M | +83.0% |
| Q4 FY2017 | Dec 31, 2017 | $3.56M | +14.4% |
| Q3 FY2017 | Sep 30, 2017 | $3.81M | – |
| Q2 FY2017 | Jun 30, 2017 | $3.40M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.06M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.11M | – |
See a number that looks wrong?